196 related articles for article (PubMed ID: 11060701)
21. [The role of cyclooxygenases in neurotoxicity of amyloid beta peptides in Alzheimer's disease].
Cakała M; Strosznajder JB
Neurol Neurochir Pol; 2010; 44(1):65-79. PubMed ID: 20358486
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells.
Ferrera P; Arias C
Neurochem Int; 2005 Dec; 47(8):589-96. PubMed ID: 16169124
[TBL] [Abstract][Full Text] [Related]
23. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology.
Hoozemans JJ; Rozemuller JM; van Haastert ES; Veerhuis R; Eikelenboom P
Curr Pharm Des; 2008; 14(14):1419-27. PubMed ID: 18537664
[TBL] [Abstract][Full Text] [Related]
24. [Preventive effects of anti-inflammatory drugs(non steroidal anti-inflammatory drugs) on Alzheimer disease].
Yamaguchi S
Nihon Rinsho; 2004 Jan; 62 Suppl():479-83. PubMed ID: 15011410
[No Abstract] [Full Text] [Related]
25. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
Meyer-Kirchrath J; Schrör K
Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
[TBL] [Abstract][Full Text] [Related]
26. [Current status of study on selective cyclooxygenase-2 inhibitors and evaluation of its application].
He W; Liu CF; Huang CQ
Di Yi Jun Yi Da Xue Xue Bao; 2002 Feb; 22(2):184-6. PubMed ID: 12390825
[TBL] [Abstract][Full Text] [Related]
27. The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs.
Hoozemans JJ; O'Banion MK
Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):307-15. PubMed ID: 15975032
[TBL] [Abstract][Full Text] [Related]
28. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation.
Thomas T; Nadackal TG; Thomas K
Neuroreport; 2001 Oct; 12(15):3263-7. PubMed ID: 11711868
[TBL] [Abstract][Full Text] [Related]
29. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease.
Hoozemans JJ; Veerhuis R; Janssen I; van Elk EJ; Rozemuller AJ; Eikelenboom P
Brain Res; 2002 Oct; 951(2):218-26. PubMed ID: 12270500
[TBL] [Abstract][Full Text] [Related]
30. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease.
Sung S; Yang H; Uryu K; Lee EB; Zhao L; Shineman D; Trojanowski JQ; Lee VM; Praticò D
Am J Pathol; 2004 Dec; 165(6):2197-206. PubMed ID: 15579461
[TBL] [Abstract][Full Text] [Related]
31. COX-1, COX-2: so what?
Emery P
Scand J Rheumatol; 1999; 28(1):6-9. PubMed ID: 10092158
[TBL] [Abstract][Full Text] [Related]
32. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain.
Hoozemans JJ; Rozemuller AJ; Janssen I; De Groot CJ; Veerhuis R; Eikelenboom P
Acta Neuropathol; 2001 Jan; 101(1):2-8. PubMed ID: 11194936
[TBL] [Abstract][Full Text] [Related]
33. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
Feldman M; McMahon AT
Ann Intern Med; 2000 Jan; 132(2):134-43. PubMed ID: 10644275
[No Abstract] [Full Text] [Related]
34. [The cardiovascular safety of cyclooxygenase-2 (COX-2) inhibitors].
Hasdai D; Gottlieb S; Godbourt U; Hod H; Kaluski E
Harefuah; 2002 Oct; 141(10):922-4. PubMed ID: 12420602
[No Abstract] [Full Text] [Related]
35. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2.
Blom MA; van Twillert MG; de Vries SC; Engels F; Finch CE; Veerhuis R; Eikelenboom P
Brain Res; 1997 Nov; 777(1-2):210-8. PubMed ID: 9449430
[TBL] [Abstract][Full Text] [Related]
36. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition.
Härtel C; von Puttkamer J; Gallner F; Strunk T; Schultz C
Scand J Immunol; 2004 Oct; 60(4):412-20. PubMed ID: 15379866
[TBL] [Abstract][Full Text] [Related]
37. COX-2 inhibitors for colorectal cancer.
Elder DJ; Paraskeva C
Nat Med; 1998 Apr; 4(4):392-3. PubMed ID: 9546780
[No Abstract] [Full Text] [Related]
38. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
Tuynman JB; Hulscher JB; Steller EP; van Lanschot JJ; Richel DJ
Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2207-12. PubMed ID: 14640057
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
40. [COX-1 and COX-2: functions and pharmacological effects].
Hinz B; Brune K
Pharm Unserer Zeit; 1999 Jan; 28(1):21-9. PubMed ID: 10078026
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
